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ongoing myocardial infarction. Patients who underwent cardiac
catheterization without an obvious culprit lesion corresponding to the
ECG changes were also included as false STEMI. The diagnoses were
obtained based upon the clinical presentation and ECG ﬁndings as
well as transthoracic echocardiogram and coronary angiography
ﬁndings in some cases.
RESULTS Of the 431 STEMI activations, (356/431) 82.6% were males
and 17.4% (75/431) were females. The overall false STEMI activation
rate was 35.3% (152/431). There were 23% (35/152) females and 77 %
(117/152) males who had false STEMI activations (p 0.023). The most
frequent cause for false STEMI activation was abnormal ECG ﬁndings-
19% (29/152), of which presumed new Left Bundle Branch Block
accounted for 48% of these. 12.5% had non cardiac chest pain (19/152)
and 11.8% (18/152) had Non STEMI (NSTEMI). Coronary artery vaso-
spasm occurred in 7.9% (12/152) of cases. Pericarditis was diagnosed in
(6.6%) 10/152 and severe hypertension in 5.9% (9/152). There were
5.2% cases (8/152) with a diagnosis of acute or decompensated
Congestive Heart Failure (CHF), unstable angina and syncope each.
4.6% (7/152) had cardiac arrest. Pericardial effusion was found in 3.3%
(5/152) patients. Three patients (2%) were diagnosed each with Bru-
gada and Takotsubo. Two patients (1.3%) had pulmonary embolism
(PE), aortic dissection and Implantable Cardioverter Deﬁbrillator (ICD)
shocks each. Less common causes were endocarditis, Intracranial
Hemorrhage (ICH), Subdural Hematoma, severe Aortic Regurgitation
(AR), severe anemia, ventricular aneurysm and sepsis where 1 case of
each was observed.
CONCLUSIONS The commonest reason for False STEMI activation
was the ﬁnding of an abnormal ECG. Presumed new LBBB accounted
for 48% of the ECG abnormalities.
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BACKGROUND Anterior ST-segment elevation infarction (A-STEMI) is
associated with larger infarct size and greater reduction in left ven-
tricular ejection fraction (LVEF) compared with non-anterior STEMI
(NA-STEMI). Whether or not ECG-deﬁned STEMI location predicts
long-term mortality after primary percutaneous coronary intervention
(PPCI) is unclear. We sought to investigate: (i) the clinical and quan-
titative coronary angiography (QCA) characteristics of patients with
ECG-deﬁned A- and NA-STEMI, and (ii) the unadjusted andindependent long-term prognostic impact of ECG-deﬁned STEMI
location in patients undergoing PPCI.
METHODS Participants from the HORIZONS-AMI trial were catego-
rized according to A-STEMI vs. NA-STEMI ECG-deﬁned STEMI loca-
tion. By ECG core laboratory analysis, A-STEMI was deﬁned as an ST-
elevation in the anterior (V2-4) or anteroseptal (V1-3) ECG leads. Pri-
mary endpoint of interest was all-cause mortality at 3 years. Adjusted
associations with 3-year mortality were estimated by Cox proportional
hazards modeling.
RESULTS Among 2,578 patients undergoing PPCI with core laboratory
determined STEMI location, 765 (29.7%) and 1813 (70.3%) hadA-STEMI and
NA-STEMI respectively. Patients with A-STEMI were older and had lower
baseline LVEF. Left anterior descending (LAD) artery was the culprit artery
in 90.9% of A-STEMIs, while the right coronary and left circumﬂex (LCX)
were the culprit arteries in 61.7% and 17.4%of NA-STEMIs, respectively. By
QCA, lesion length was longer, and thrombus, calciﬁcation, and type B2/C
lesions were more prevalent in NA-STEMI. At 3 years, patients with A-
STEMI had higher unadjusted rates of 3-year all-cause mortality (7.6% vs.
4.8%; p¼ 0.004). This association persisted aftermultivariable adjustment
for baseline clinical confounders (hazard ratio [HR]: 1.42; 95% conﬁdence
interval [CI]: 1.19 – 1.69; p<0.0001). However, after includingQCAvariables
in the multivariable model, ECG-deﬁned A-STEMI had no effect on 3-year
mortality (HR: 1.03; 95% CI: 0.77 – 1.37; p¼0.84); conversely, QCA variables
such as LAD as a culprit artery, presence of LCX plaques with > 50% di-
ameters stenosis (DS), presence of left main plaques with > 50% DS, and
total lesion length did.
CONCLUSIONS ECG-deﬁned A-STEMI was associated with greater
long-term mortality in patients undergoing primary PCI from HORI-
ZONS-AMI. QCA variables, however, including infarct artery location,
had better long-term prognostic value than ECG-deﬁned STEMI
location.
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BACKGROUND It is known that elevated inﬂammatory biomarkers
were associated with clinical outcomes of patients with ST-segment
elevated myocardial infarction (STEMI). This study investigated the
usefulness of a novel inﬂammation-based prognostic system, named
the combination of platelet count and neutrophil-lymphocyte ratio
(COP-NLR) for predicting prognosis of patients with STEMI.
METHODS We analysis 305 consecutive patients with STEMI treated
with primary PCI. The COP-NLR was calculated as follows: patients
with both an elevated platelet count (> 300  109/l) and neutrophil
lymphocyte ratio (> 3) were allocated a score of 2 and patients
showing one or neither were allocated a score of 1 or 0, respectively.
RESULTS The patients with COP-NLR score 0, 1, and 2 was 102, 149,
and 23 patients, respectively. The peak CK-MB (181.4 ng/ml, 219.7 ng/
ml, and 265.1 ng/ml, respectively, ANOVA P ¼ 0.070) and Troponin T
numerically increased according to COP-NLR score (0.63 ng/ml, 0.78
ng/ml, and 1.57 ng/ml, respectively, ANOVA P ¼ 0.059). During the
PCI, no-reﬂow tended to be observed more frequently in patients with
score 2 (2.8%, 4.7%, and 10.3%, respectively, P ¼ 0.117).The in-hospital
mortality was highest in COP-NLR score 2 (0%, 4.7%, and 13.8%,
respectively, P ¼ 0.002). The Kaplan-Meier curve showed that higher
COP-NLR score signiﬁcantly associated with major cardiovascular
adverse events in 12-month follow-up.
Short-term and long-term clinical outcomes according to COP-NLR scoreCOP-NLR score 0
N [ 106COP-NLR score 1
N [ 161COP-NLR score 2
N[25 P-valueIn-hospital death 0, 0% 8, 4.7% 4, 13.8% 0.001All cause death 0, 0% 9, 5.3% 4, 13.8% 0.003Non-fatal MI 3, 2.8% 3, 1.8% 1, 3.4% 0.771TLR 5, 4.7% 3, 1.8% 0, 5% 0.231MACE 7, 6.6% 16, 9.4% 6, 20.7% 0.072
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system, could predict short term and long term clinical outcomes of
patients with STEMI.
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BACKGROUND Intra-aortic balloon pump (IABP) therapy is a widely
used intervention for acute myocardial infarction with shock. Guide-
lines, which previously strongly recommended it, have recently un-
dergone substantial change.We sought to synthesize all available study
evidence on the use of IABP therapy in acute myocardial infarction.
METHODS We performed a meta-analysis of all randomized and
observational trials. To assess the baseline inequality between treat-
ment and control groups in observational studies, and its relationship
with apparent beneﬁt, we devised a simple baseline inequality index.
We then performed a random-effects meta-regression to assess mor-
tality adjusted for the baseline risk.
RESULTS There were 12 eligible RCTs randomizing 2,123 patients. In
the RCTs, IABP had no statistically signiﬁcant effect on mortality,
odds ratio (OR) 0.96, 95% conﬁdence interval (CI) 0.74 to 1.24, with no
signiﬁcant heterogeneity between trials (I2¼0%, p¼0.52). This result
was consistent even when studies were stratiﬁed by the presence or
absence of shock: OR in those with shock 0.94 (95% CI 0.69 to 1.28,
p¼0.69 , I2¼0%), OR in those without shock 0.98 (95% CI 0.57 to 1.69,
p¼0.95, I2¼17%). There were 15 eligible observational studies totaling
15,530 patients. Their results were extensively mutually conﬂicting
(heterogeneity I2¼97%, p<0.001), causing wide uncertainty in the
summary estimate for the association with mortality (OR 0.96, CI 0.54
to 1.70). A simple index of baseline risk marker imbalance in the
observational studies appeared to explain much of the heterogeneity
in the observational data (R2meta¼46.2%, p<0.001).CONCLUSIONS IABP therapy was not found to improve mortality among
patients with AMI in the RCTs, regardless of whether patients had cardio-
genic shock or not. The observational studies showed a variety ofmutually
contradictory associations between IABP therapy and mortality, much of
which was explained by the differences between studies in the balance of
risk factors between IABP and non-IABP groups.
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BACKGROUND Thrombus aspiration is a mechanistically logical
adjunct in primary angioplasty for acute myocardial infarction. Indi-
vidual randomized controlled trials (RCTs) have not shown a
consensus of mortality reduction and there are concerns about stroke.
We perform a meta-analysis of all available RCT data on thrombus
aspiration, including the large, recently published TOTAL trial.
METHODS A meta-analysis of RCTs of thrombus aspiration, including
the recent TOTAL data was performed. The primary efﬁcacy endpoint
was mortality, and the primary safety endpoint was stroke. Outcomes
were assessed both at the short-term (30-days) and longer-term (6-12
months) timepoints. We then consider the number of patients that
would be required to adequately power a trial for a new therapy in
STEMI, considering the control arm mortality observed in contem-
porary randomized trials.
RESULTS At 30 days (11 trials; 20,192 patients) there was a marginally
non-signiﬁcant reduction in all cause-mortality with thrombus aspi-
ration (OR 0.844, 95% CI 0.710-1.003, p¼0.05). The longer-term
follow-up data (13 trials; 20,142 patients) was similarly non-signiﬁcant
(OR 0.89, 95% CI 0.78-1.01, p¼0.08). At both 30 days and longer-term
follow-up, there was a statistically signiﬁcant increase in stroke with
thrombus aspiration (OR 1.56, 95% CI 1.05 to 2.32, p¼0.03, and OR
1.94, 95% CI 1.24 to 3.04, p¼0.04 respectively). The mortality of
STEMI in control arms of trials is 3.0%. To reliably detect a statistically
signiﬁcant 10% relative risk reduction in STEMI mortality from 3.0%
to 2.7% would require almost 100,000 patients.
